首页> 外文期刊>Japanese journal of clinical oncology. >Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis
【24h】

Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis

机译:后移植后环磷酰胺基于同型移植与脐带血液移植; 荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Both haplo-identical transplant (haplo) and umbilical cord transplant (UC) are valuable graft options for patients without available matched relative. Previous studies showed inconsistent outcomes comparing Post transplant Cyclophosphamide based haplo (PTCy-haplo) and UC; therefore, we attempt to compare the studies by mean of meta-analysis. Methods: We searched for titles of articles in MEDLINE (PubMed), Cochrane library, EMBASE database and Google scholar that compared transplantation with PTCy-haplo versus UC. We conducted a random-effect meta-analysis of seven studies involving a total of 3434 participants and reported the pooled odd ratios (OR) of acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), relapse and overall survival (OS) between PTCy-haplo and UC groups. Results: We found a significantly decreased risk of aGVHD and relapse in the PTCy-haplo group compared to the UC group with a pooled OR of 0.78, 95% Confidence Interval (CI) 0.67-0.92, I~2=0%, and 0.74, 95% CI 0.57-0.97, I~2=23.9% respectively. We also found a significantly increased rate of cGVHD and OS with a pooled OR of 1.41, 95% CI 1.02-1.95, I~2=56.8%, and 1.77, 95% CI 1.1-2.87, I~2=82.5%, respectively. Conclusion: Our meta-analysis of clinical trials demonstrated superior outcome from PTCgamma-haplo group compared to the UC group in terms of decreased rate of aGVHD and relapse as well as the increased rate of OS but inferior in terms of increased cGVHD risk compared to UC transplant.
机译:目的:HAPLO相同的移植(HAPLO)和脐带移植(UC)是没有可用相对的患者的有价值的移植选项。先前的研究表明,比较移植后的环磷酰胺的HAPLO(PTCY-HAPLO)和UC的不一致结果;因此,我们试图通过Meta分析的平均值进行比较。方法:我们搜索了Medline(PubMed),Cochrane图书馆,EMBASE数据库和Google学者的文章的标题,将与PTCY-HAPLO与UC进行移植。我们对七项研究进行了随机效应的荟萃分析,涉及共3434名参与者,并报告了急性移植物与宿主疾病(AGVHD),慢性接枝与宿主疾病(CGVHD)的合并奇数比例(或), PTCY-HAPLO和UC组之间的复发和整体生存(OS)。结果:我们发现与汇集的UC组或0.78,95%置信区间(CI)0.67-0.92,I〜2 = 0%和0.74的UC组(I〜2 = 0%)相比,PTCY-HAPLO组的agvHD风险显着降低了PTCY-HAPLO组的风险。 ,95%CI 0.57-0.97,I〜2 = 23.9%。我们还发现汇集或1.41,95%CI 1.02-1.95,I〜2 = 56.8%和1.77,95%CI 1.1-2.87,I〜2 = 82.5% 。结论:我们对临床试验的META分析表现出PTCGAMMA-HAPLO组的优越结果与UC组在AGVHD和复发率下降方面与UC组相比,以及与UC相比增加了CGVHD风险的次数而是较差的移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号